CPL develops, manufactures, packages, and tests non-sterile liquid and semi-solid pharmaceutical products. We are solely focused on these dosage forms, and it’s this focus that has earned us our reputation as an industry leader, perfecting our capabilities in each of these areas.
Our facilities are registered with the U.S. FDA, Health Canada, and have been inspected by the Japanese Health Authority. There is also a Mutual Recognition Agreement between Canada and the European Union and Australia that allows products to be easily released to those regions. These and other international agencies routinely inspect our facilities through GMP or Pre-Approval Inspections, and our compliance team regularly hosts audits with current and prospective customers.
Our product development team consists of 35 people with over 400 collective years of formulation development and analytical experience combined. This team strives to find the balance between scientific rigor and short, efficient timelines.
CPL offers elemental impurities testing services to current customers with development and/or commercial manufacturing programs and as a fee-for-service for companies who require testing. With state-of-the-art ICP-MS equipment and world-class analysts, CPL is capable of quantifying elements at the parts-per-billion level in compliance with USP <232> and <233>, EP, and ICH Q3D guidelines.